As psychedelic medicalization and the potential profits of a “virgin market” loom large, new organizations are increasingly looking to gain legitimacy within the field. Mainstreaming means the doors of this field are being thrown wide open.

As venture-capital-backed, for-profit companies barrel into psychedelic therapy, the potential for the widespread privatization of psychedelic knowledge and profits looms large. Some researchers are so enthusiastic about medicalization by “any means necessary” that they’re resorting to prohibitionist historical narratives and calling for monopolies to push the agenda forward.

I first discovered the potential psychedelics have for treating stuttering during an experience with psilocybin mushrooms.

The Ibogaine Conversation Conclusion | The goal of this conversation was to provide a platform for a diverse range of perspectives on a single topic. Not everyone agrees, and that’s the point.

The Ibogaine Conversation Part 10 | Unlike other psychedelic drugs, ibogaine is known to be potentially cardiotoxic. There are a number of fatalities associated with its use, and anyone considering working with it should be aware of the risks.

The Ibogaine Conversation Part 9 | Using ibogaine can be fatal if proper safety precautions aren’t taken.

The Ibogaine Conversation Part 7 | "Prescription is not about accessibility, by definition it’s about restriction. Unless we start to use psychedelics as a way to tear apart these structures and build new ones in their place, then I think it's all a revolving door."

The Ibogaine Conversation Part 6 | My experience with heroin went from age 14 up to age 30, and taking ibogaine was as close to a miracle as I have ever experienced in my life.

The Ibogaine Conversation Part 5 | Thomas Kingsley Brown, PhD, studied the long-term outcomes of people who received ibogaine for the treatment of opioid addiction. We talked about the results.